Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
ConclusionBinimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring KRAS mutations.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | CT Scan | Hormones | Oral Cancer | Ovarian Cancer | Ovaries | PET Scan | Serous Carcinoma | Toxicology